<DOC>
	<DOC>NCT00847145</DOC>
	<brief_summary>The proposed study is an Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers</brief_summary>
	<brief_title>Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy 12monthold toddlers (0/ +29 days) who completed Study V72P13 Previous ascertained or suspected disease caused by N. meningitidis; History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component; Any serious chronic or progressive disease Known or suspected impairment/ alteration of the immune system, Receipt of, or intent to immunize with another vaccine, within 30 days prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>365 Days</minimum_age>
	<maximum_age>394 Days</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>toddler</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
</DOC>